274
Participants
Start Date
July 26, 2005
Primary Completion Date
June 13, 2007
Study Completion Date
June 13, 2007
salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training
Salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training will be provided to intervention group in Period 2.
salmeterol/fluticasone propionate 50/250 µg
Salmeterol/fluticasone propionate 50/250 µg will be administered to control group in Period 2
GSK Investigational Site, København NV
GSK Investigational Site, Hvidovre
GSK Investigational Site, Bern
GSK Investigational Site, Bern
GSK Investigational Site, Bern
GSK Investigational Site, Worb
GSK Investigational Site, Düdingen
GSK Investigational Site, Thun
GSK Investigational Site, Basel
GSK Investigational Site, Basel
GSK Investigational Site, Basel
GSK Investigational Site, Basel
GSK Investigational Site, Basel
GSK Investigational Site, Allschwil
GSK Investigational Site, Næstved
GSK Investigational Site, Brittnau
GSK Investigational Site, Odense C
GSK Investigational Site, Aarau
GSK Investigational Site, Horw
GSK Investigational Site, Castione
GSK Investigational Site, Malvaglia
GSK Investigational Site, Massagno
GSK Investigational Site, Pregassona
GSK Investigational Site, Klosters Platz
GSK Investigational Site, Bever
GSK Investigational Site, Egg
GSK Investigational Site, Steckborn
GSK Investigational Site, Wigoltingen
GSK Investigational Site, Wald
GSK Investigational Site, Faltigberg-Wald
GSK Investigational Site, Aalborg
GSK Investigational Site, Aarhus C
Lead Sponsor
GlaxoSmithKline
INDUSTRY